Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: R-Flurbiprofen; E-7869; Flurizan; MPC-7869; TMP-001; TruNoc

Latest Information Update: 11 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Loma Linda University Medical Center
  • Developer Fraunhofer Institute for Molecular Biology and Applied Ecology; Horizon Pharma AG; Myriad Pharmaceuticals
  • Class Antidementias; Antineoplastics; Biphenyl compounds; Propionic acids; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase modulators; NF-kappa B inhibitors; Transcription factor AP-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis
  • Discontinued Alzheimer's disease; Inflammation; Pain; Prostate cancer

Most Recent Events

  • 11 Mar 2019 Tarenflurbil is still in phase II trials for Multiple Sclerosis in Germany (NCT02686788)
  • 15 Mar 2016 Biomarkers information updated
  • 16 Jul 2015 Phase-II clinical trials in Multiple sclerosis (Relapsing, remitting) in Germany (PO) (EudraCT2014-004483-38)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top